Primary malignant melanoma of the breast: A case report and review of the literature

He,Yujun; Mou,Jianghong; Luo,Donglin; Gao,Bo; Wen,Yayuan

doi:10.3892/ol.2014.2120

Primary malignant melanoma of the breast: A case report and review of the literature

Authors:
- Yujun He
- Jianghong Mou
- Donglin Luo
- Bo Gao
- Yayuan Wen
View Affiliations

Affiliations: Department of General Surgery, Daping Hospital and Research Institute of Surgery, Third Military Medical University, Chongqing 400042, P.R. China, Department of Pathology, Daping Hospital and Research Institute of Surgery, Third Military Medical University, Chongqing 400042, P.R. China
Published online on: May 7, 2014 https://doi.org/10.3892/ol.2014.2120
Pages: 238-240

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Malignant melanoma predominantly occurs in the skin and mucous membranes, thus, malignant melanoma of the breast is particularly rare. In the current study, a case of a 26‑year‑old female with a malignant melanoma of the breast is presented. On diagnosis of the patient, extensive metastasis had occurred. The patient refused any treatment and succumbed two months after the initial diagnosis. The prognosis for patients with this rare tumour of the breast is somewhat poor. Early diagnosis, correct surgical resection and comprehensive adjuvant therapy are the key procedures that may improve the patient survival rate. The current case report aims to increase the awareness of uncommon tumours of the breast.

View Figures

View References

1	Kurul S, Taş F, Büyükbabani N, et al: Different manifestations of malignant melanoma in the breast: a report of 12 cases and a review of the literature. Jpn J Clin Oncol. 35:202–206. 2005.
2	Alzaraa A and Sharma N: Primary cutaneous melanoma of the breast: A case report. Cases J. 1:2122008.
3	Duggal R and Srinivasan R: Primary amelanotic melanoma of the cervix: case report with review of literature. J Gynecol Oncol. 21:199–202. 2010.
4	Bonetti F, Pea M, Martignoni G, et al: False-positive immunostaining of normal epithelia and carcinomas with ascites fluid preparations of antimelanoma monoclonal antibody HMB45. Am J Clin Pathol. 95:454–459. 1991.
5	Taatjes DJ, Arendash-Durand B, von Turkovich M and Trainer TD: HMB-45 antibody demonstrates melanosome specificity by immunoelectron microscopy. Arch Pathol Lab Med. 117:264–268. 1993.
6	Ohsie SJ, Sarantopoulos GP, Cochran AJ and Binder SW: Immunohistochemical characteristics of melanoma. J Cutan Pathol. 35:433–444. 2008.
7	Lee AH: Use of immunohistochemistry in the diagnosis of problematic breast lesions. J Clin Pathol. 66:471–477. 2013.
8	Davar D, Tarhini AA and Kirkwood JM: Adjuvant therapy for melanoma. Cancer J. 18:192–202. 2012.
9	Biswas A, Goyal S, Jain A, et al: Primary amelanotic melanoma of the breast: combating a rare cancer. Breast Cancer. 21:236–240. 2014.
10	Thompson JF, McCarthy WH, Bosch CM, et al: Sentinel lymph node status as an indicator of the presence of metastatic melanoma in regional lymph nodes. Melanoma Res. 5:255–260. 1995.
11	Avril MF, Aamdal S, Grob JJ, et al: Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol. 22:1118–11125. 2004.
12	Lee RJ, Gibbs JF, Proulx GM, et al: Nodal basin recurrence following lymph node dissection for melanoma: implications for adjuvant radiotherapy. Int J Radiat Oncol Biol Phys. 46:467–474. 2000.
13	Calabro A, Singletary SE and Balch CM: Patterns of relapse in 1001 consecutive patients with melanoma nodal metastases. Arch Surg. 124:1051–1055. 1989.
14	Thompson JF, Scolyer RA and Kefford RF: Cutaneous melanoma. Lancet. 365:687–701. 2005.
15	Verma S, Quirt I, McCready D, et al: Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma. Cancer. 106:1431–1442. 2006.
16	Hauschild A, Weichenthal M, Rass K, et al: Efficacy of low-dose interferon α2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: results of a randomized phase III DeCOG trial. J Clin Oncol. 28:841–846. 2010.
17	Chapman PB, Hauschild A, Robert C, et al; BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 364:2507–2516. 2011.
18	Ribas A, Hersey P, Middleton MR, et al: New challenges in endpoints for drug development in advanced melanoma. Clin Cancer Res. 18:336–41. 2012.
19	Spagnolo F and Queirolo P: Upcoming strategies for the treatment of metastatic melanoma. Arch Dermatol Res. 304:177–184. 2012.